Radiobiological response of U251MG, CHO-K1 and V79 cell lines to accelerator-based boron neutron capture therapy

Eisuke Sato, Alexander Zaboronok, Tetsuya Yamamoto, Kei Nakai, Sergey Taskaev, Olga Volkova, Ludmila Mechetina, Alexander Taranin, Vladimir Kanygin, Tomonori Isobe, Bryan J. Mathis, Akira Matsumura

Research output: Contribution to journalArticlepeer-review

17 Citations (Scopus)

Abstract

In the current article, we provide in vitro efficacy evaluation of a unique accelerator-based neutron source, constructed at the Budker Institute of Nuclear Physics (Novosibirsk, Russian Federation), for boron neutron capture therapy (BNCT), which is particularly effective in the case of invasive cancers. U251MG, CHO-K1 and V79 cells were incubated and irradiated in various concentrations of boric acid with epithermal neutrons for 2–3 h in a plexiglass phantom, using 2.0 MeV proton energy and 1.5–3.0 mA proton current, resulting in a neutron fluence of 2.16 × 1012 cm−2. The survival curves of cells loaded with boron were normalized to those irradiated without boron (to exclude the influence of the fast neutron and gamma dose components) and fit to the linear–quadratic (LQ) model. Colony formation assays showed the following cell survival rates (means ± SDs): CHO-K1: 0.348 ± 0.069 (10 ppm), 0.058 ± 0.017 (20 ppm), 0.018 ± 0.005 (40 ppm); V79: 0.476 ± 0.160 (10 ppm), 0.346 ± 0.053 (20 ppm), 0.078 ± 0.015 (40 ppm); and U251MG: 0.311 ± 0.061 (10 ppm), 0.131 ± 0.022 (20 ppm), 0.020 ± 0.010 (40 ppm). The difference between treated cells and controls was significant in all cases (P < 0.01) and confirmed that the neutron source and irradiation regimen were sufficient for control over cell colony formation. We believe our study will serve as a model for ongoing in vitro experiments on neutron capture therapy to advance in this area for further development of accelerator-based BNCT into the clinical phase.

Original languageEnglish
Pages (from-to)101-107
Number of pages7
JournalJournal of Radiation Research
Volume59
Issue number2
DOIs
Publication statusPublished - 1 Mar 2018

Keywords

  • Accelerator-based neutron source
  • Boric acid
  • Boron neutron capture therapy
  • In vitro efficacy evaluation
  • Lithium target
  • boric acid
  • TARGET
  • TSUKUBA
  • boron neutron capture therapy
  • BNCT
  • lithium target
  • NECK-CANCER
  • accelerator-based neutron source
  • NANOPARTICLES
  • IN-VITRO
  • GLIOBLASTOMA
  • TRANSPORT
  • RECURRENT HEAD
  • in vitro efficacy evaluation

Fingerprint

Dive into the research topics of 'Radiobiological response of U251MG, CHO-K1 and V79 cell lines to accelerator-based boron neutron capture therapy'. Together they form a unique fingerprint.

Cite this